Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator ...
Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback